RenovoRx (RNXT) Stock: Buy, Sell, or Hold?
RNXT - RenovoRx, Inc. Common Stock
$1.29
0.02 (1.57%)
▲
5d:
+13.16%
30d:
-23.21%
90d:
+33.66%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When RNXT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RNXT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: RNXT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: RNXT is currently trading at $1.29, which is considered slightly low relative to its 30-day fair value range of $1.23 to $1.64.
Technical Outlook: Technically, RNXT is in a uptrend. The price is approaching resistance at $1.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RNXT scores 89/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.12 (+452.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RNXT is in a uptrend. The price is approaching resistance at $1.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RNXT scores 89/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.12 (+452.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.23 -
$1.64
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (89/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 452.3% below Wall St target ($7.12)
- BULLISH: Bottoming setup score 89/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.23 -
$1.64
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$1.32
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.75
Wall Street Target
$7.13
(+452.3%)
Revenue Growth (YoY)
115.4%
Share & Embed Analysis
Last updated: October 24, 2026 5:04 AM ET
Data refreshes hourly during market hours. Next update: 6:04 AM
Data refreshes hourly during market hours. Next update: 6:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNXT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
